Anti-C3b Antibodies Inhibit Complement Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective drugs that specifically inhibit complement activation, which contributes to tissue injury in various disease states such as septic shock, myocardial infarction, and autoimmune disorders, despite its role in inflammatory responses and organ damage.
Innovation Solution
Development of anti-C3b antibodies or fragments that inhibit C3b-dependent complement activation by limiting C3 cleavage and binding of C3b to factor B and properdin, effectively blocking all three complement pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If complement activation is allowed to proceed, then protective inflammatory response is initiated, but tissue injury and organ damage occur
Solution Approach 1:
The patent extracts and isolates the harmful component (C3b) from the complement system while preserving the overall protective function. By specifically targeting and inhibiting C3b, the invention separates the beneficial inflammatory response from the harmful tissue injury, allowing the former to continue while blocking the latter.
Solution Approach 2:
The patent introduces an intermediary substance (anti-C3b antibody or C3b inhibitor) that mediates between the complement system and host tissues. This intermediary selectively binds to C3b, preventing it from causing tissue damage while allowing other complement components to maintain protective functions.
2Object-affected harmful factors
If complement activation is inhibited, then tissue injury is reduced, but protective immune defense is compromised
Solution Approach 1:
The invention extracts only the specific harmful element (C3b) from the complement cascade, rather than inhibiting the entire complement system. This selective extraction preserves the protective functions of other complement components while eliminating the tissue-damaging effects.
Solution Approach 2:
The patent applies local quality by targeting a specific component (C3b) within the complement system rather than applying a global inhibition. The anti-C3b antibody selectively binds to C3b molecules, creating a localized effect that preserves the quality and function of other complement components.
3Reliability
If C3b binding to factor B and properdin is prevented, then alternative pathway activation is blocked, but specificity and manufacturing precision of the inhibitor must be high
Solution Approach 1:
The patent uses antibody molecules that naturally copy the high-specificity binding mechanism of the immune system. The anti-C3b antibody employs the same precise recognition and binding principles that antibodies use to identify specific antigens, achieving high specificity through a proven biological mechanism rather than requiring complex synthetic precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of anti-C3b antibodies significantly reduces complement activation, providing therapeutic benefits in treating conditions like ischemia reperfusion injuries, atherosclerosis, inflammatory gastrointestinal disorders, and autoimmune diseases by mitigating tissue damage and inflammatory responses.
Implementation Method 1
anti-C3b antibodies or fragments that inhibit C3b-dependent complement activation by limiting C3 cleavage and binding of C3b to factor B and properdin
Data Source
AI summary
A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3B inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC.